Wormser Freres Gestion Buys 814 Shares of Stryker Corporation $SYK

Key Points

• Wormser Freres Gestion increased its stake in Stryker Corporation by 3.2% in Q1, owning 26,403 shares, making Stryker its 4th largest holding worth approximately $9.66 million.
• In a recent transaction, Director Ronda E. Stryker sold 200,000 shares for $75.29 million, reducing her position by 5.84%.
• Stryker reported Q2 earnings of $3.13 per share, exceeding analysts' estimates, with revenues of $6.02 billion, an 11.1% year-over-year increase.

Wormser Freres Gestion grew its position in Stryker Corporation (NYSE:SYK - Free Report) by 3.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,403 shares of the medical technology company's stock after purchasing an additional 814 shares during the period. Stryker makes up approximately 5.9% of Wormser Freres Gestion's investment portfolio, making the stock its 4th largest holding. Wormser Freres Gestion's holdings in Stryker were worth $9,661,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of SYK. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares in the last quarter. MML Investors Services LLC increased its position in shares of Stryker by 8.8% in the fourth quarter. MML Investors Services LLC now owns 38,491 shares of the medical technology company's stock valued at $13,859,000 after acquiring an additional 3,099 shares during the last quarter. J. Safra Sarasin Holding AG increased its position in shares of Stryker by 66.6% in the fourth quarter. J. Safra Sarasin Holding AG now owns 2,497 shares of the medical technology company's stock valued at $899,000 after acquiring an additional 998 shares during the last quarter. Dark Forest Capital Management LP increased its position in shares of Stryker by 3.3% in the fourth quarter. Dark Forest Capital Management LP now owns 2,483 shares of the medical technology company's stock valued at $894,000 after acquiring an additional 79 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Stryker by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after acquiring an additional 54,693 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.90% of the company's stock.

Stryker Stock Performance

Shares of Stryker stock traded up $8.9740 on Friday, hitting $393.8040. The stock had a trading volume of 896,076 shares, compared to its average volume of 1,348,874. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The business's 50 day moving average is $387.51 and its two-hundred day moving average is $379.37. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market cap of $150.56 billion, a price-to-earnings ratio of 52.16, a price-to-earnings-growth ratio of 2.86 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the prior year, the business earned $2.81 earnings per share. The firm's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio is presently 44.50%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. Needham & Company LLC lifted their target price on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Truist Financial set a $415.00 target price on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Finally, JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and an average price target of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.